Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pmv Pharmaceuticals Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a distinct examiner and a distinct art unit, showing a fully distributed prosecution profile within the listed portfolio.
TURPIN, ZACHARY MARK is the busiest examiner, with 1 pending matter. Because the matters are not concentrated under a shared examiner or art unit, counsel may benefit from separate response planning while preserving consistent treatment of related technical and claim issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854275 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TURPIN, ZACHARY MARK | — |
| 18421550 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18421550 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PUTTLITZ, KARL J | — |
| 17679568 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | JOHNSON, CHRISTOPHER LINDSAY | — |
| 17348488 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1646 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854275 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TURPIN, ZACHARY MARK | 1682 | §102§103§112Other | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18421550 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PUTTLITZ, KARL J | 1646 | §103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 17679568 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112Other | Non-Final OA | — | Pending | Feb 24, 2022 |
| 17348488 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Final Rejection | — | Pending | Jun 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPmv Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Zachary Mark Turpin has the most, with 1 of Pmv Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
